On Jul. 21, 2020, GlaxoSmithKline and CureVac announced a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSKﾒs existing mRNA capabilities with CureVacﾒs integrated mRNA platform.